- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
- TScan Therapeutics Announces Closing of Upsized Public Offering
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
- TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.79 |
---|---|
High | 9.09 |
Low | 8.55 |
Bid | 8.25 |
Offer | 9.00 |
Previous close | 8.65 |
Average volume | 174.92k |
---|---|
Shares outstanding | 50.30m |
Free float | 45.61m |
P/E (TTM) | -- |
Market cap | 430.59m USD |
EPS (TTM) | -2.49 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼